HC Wainwright Comments on Savara’s Q1 Earnings (NASDAQ:SVRA)

Savara Inc. (NASDAQ:SVRA) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Savara in a research report issued on Monday, March 16th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.09) EPS, FY2029 earnings at $0.41 EPS and FY2030 earnings at $0.72 EPS.

Other research analysts have also recently issued reports about the stock. UBS Group set a $10.00 price target on shares of Savara in a report on Tuesday, December 23rd. William Blair set a $10.00 price objective on Savara in a report on Monday. Guggenheim reiterated a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. Oppenheimer set a $10.00 target price on Savara in a research note on Tuesday, December 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Savara Stock Down 0.4%

Shares of NASDAQ:SVRA opened at $5.23 on Tuesday. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $7.01. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm’s 50-day simple moving average is $5.66 and its 200-day simple moving average is $4.98. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -9.87 and a beta of 0.31.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Trading of Savara

Several large investors have recently modified their holdings of the business. VR Adviser LLC raised its position in shares of Savara by 8.4% during the 4th quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after purchasing an additional 1,059,332 shares during the last quarter. Vanguard Group Inc. grew its holdings in Savara by 20.8% during the 4th quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock valued at $60,551,000 after buying an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in Savara by 5.4% during the 3rd quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after buying an additional 450,000 shares during the last quarter. Polar Capital Holdings Plc purchased a new position in Savara during the fourth quarter worth $50,086,000. Finally, RTW Investments LP purchased a new position in Savara during the fourth quarter worth $35,893,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.